| |
ACCORD |
ADVANCE |
VADT |
| N |
10,251 |
11,140 |
1791 |
| Age (mean, years) |
62 |
66 |
60 |
| BMI (mean, kg/m2) |
32 |
28 |
31 |
| Follow-up (mean, years) |
3.5 |
5 |
5.6 |
| A1c target |
<6.0% versus 7.0%-7.9% |
≤6.5% versus “standard” |
<6% versus 8%-9% |
| Baseline A1c (mean) |
8.3% |
7.5% |
9.4% |
| Endpoint A1c (mean) |
Intensive 6.4% |
Standard 7.5% |
Intensive 6.43% |
Standard 7.0% |
Intensive 6.9% |
Standard 8.4% |
| Severe hypoglycemic events |
Intensive 10.5% |
Standard 3.5% |
Intensive 2.7% |
Standard 1.5% |
Intensive 8.5% |
Standard 2.1% |
| Weight change |
Intensive +3.5 kg |
Standard +0.4 kg |
Intensive −0.1 kg |
Standard −1.0 kg |
Intensive +8.1% |
Standard +4.1% |
| Major macrovascular or microvascular event |
Not reported |
0.9 (0.82-0.98), P = 0.01 |
0.88 (0.74-1.05), P = 0.14 |
| Nonfatal MI/stroke, CV death |
HR 0.9 (0.78-1.04), P = 0.16 |
0.94 (0.84-1.06), P = 0.32 |
Not reported |
| All-cause mortality |
HR 1.22 (1.01-1.46), P = 0.04 |
0.93 (0.83-1.06), P = 0.28 |
1.07 (0.81-1.42), P = 0.62 |
| Nonfatal MI |
HR 0.76 (0.62-0.92), P = 0.004 |
0.98 (0.77-1.22), P = NS |
0.82 (059-1.14), P = 0.24 |
ACCORD: Action to Control Cardiovascular Risk in Diabetes trial; ADVANCE: Action in Diabetes and Vascular Disease: preterAx and diamicro N-MR Controlled Evaluation
trial; A1c: Gglycosylated Hemoglobin; BMI: Body Mass Index; CV: Cardiovascular; MI: Myocardial Infarction; VADT: Veterans Affairs Diabetes Trial |
